Ischemia-modified albumin appears in the serum within minutes of ischemia, before myocete necrosis, and can be detected 6 hours or more after the onset of symptoms.
In this issue of CMAJ, Worster and colleagues describe how they evaluated the prognostic capabilities of high or low levels of ischemia-modified albumin in patients with potential cardiac-ischemia symptoms (within the preceding 6 hours) by recording outcomes such as death, myocardial infarction, heart failure, arrhythmia and refractory pain within 3 days of presentation. Their analysis, as underlined by Sabatine in a related commentary, showed that levels of ischemia-modified albumin provided no useful information in predicting which patients would have a serious cardiac outcome in the short term.
Source: Eurekalert & others
Published on PsychCentral.com. All rights reserved.
The Difficult is that which can be done immediately; the Impossible that which takes a little longer.
~ George Santayana